FindTrial
Sign In

Decitibine combined with activated DLI for acute myeloid leukemia patients with hematologic relapse after allogeneic hematopoietic stem cell transplantation: a single arm prespective clinical trial

Decitibine combined with activated DLI for acute myeloid leukemia patients with hematologic relapse after allogeneic hematopoietic stem cell transplantation: a single arm prospective clinical trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-16007757
Enrollment
Unknown
Registered
2016-01-16
Start date
2016-01-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

decitibine and aDLI group:decitibine, IFN-?-2b and DLI

Sponsors

the First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. with inform consent; 2. AML patients with hematologic relapse after allogeneic hematopoietic stem cell transplantation; 3. No contraindication for therapy: active infection, liver and renal function damage.

Exclusion criteria

Exclusion criteria: 1. uncontrolled active GVHD; 2. uncontrolled severe infection; 3. organ failure; 4. death may occur within 30 days of the expected recurrence

Design outcomes

Primary

MeasureTime frame
Disease Response;Disease-free survival;Overall Survival;—

Secondary

MeasureTime frame
Toxicity;Graft-versus-host disease;—

Countries

China

Contacts

Public ContactWu Depei?Tang Xiaowen
xwtang1020@163.com+86 13913538266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026